DrugPatentWatch Database Preview
Upadacitinib - Generic Drug Details
What are the generic drug sources for upadacitinib and what is the scope of freedom to operate?
Upadacitinib
is the generic ingredient in one branded drug marketed by Abbvie Inc and is included in one NDA. There are eight patents protecting this compound. Additional information is available in the individual branded drug profile pages.Upadacitinib has one hundred and fifty-one patent family members in forty-one countries.
One supplier is listed for this compound.
Summary for upadacitinib
| International Patents: | 151 |
| US Patents: | 8 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 35 |
| Clinical Trials: | 41 |
| Patent Applications: | 288 |
| What excipients (inactive ingredients) are in upadacitinib? | upadacitinib excipients list |
| DailyMed Link: | upadacitinib at DailyMed |
Recent Clinical Trials for upadacitinib
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Pfizer | Phase 4 |
| Bristol-Myers Squibb | Phase 4 |
| University of Nebraska | Phase 4 |
US Patents and Regulatory Information for upadacitinib
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbvie Inc | RINVOQ | upadacitinib | TABLET, EXTENDED RELEASE;ORAL | 211675-001 | Aug 16, 2019 | RX | Yes | Yes | ⤷ Try it Free | ⤷ Try it Free | Y | Y | ⤷ Try it Free | ||
| Abbvie Inc | RINVOQ | upadacitinib | TABLET, EXTENDED RELEASE;ORAL | 211675-001 | Aug 16, 2019 | RX | Yes | Yes | ⤷ Try it Free | ⤷ Try it Free | Y | ⤷ Try it Free | |||
| Abbvie Inc | RINVOQ | upadacitinib | TABLET, EXTENDED RELEASE;ORAL | 211675-001 | Aug 16, 2019 | RX | Yes | Yes | ⤷ Try it Free | ⤷ Try it Free | Y | ⤷ Try it Free | |||
| Abbvie Inc | RINVOQ | upadacitinib | TABLET, EXTENDED RELEASE;ORAL | 211675-001 | Aug 16, 2019 | RX | Yes | Yes | ⤷ Try it Free | ⤷ Try it Free | ⤷ Try it Free | ||||
| Abbvie Inc | RINVOQ | upadacitinib | TABLET, EXTENDED RELEASE;ORAL | 211675-001 | Aug 16, 2019 | RX | Yes | Yes | ⤷ Try it Free | ⤷ Try it Free | Y | ⤷ Try it Free | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for upadacitinib
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Hong Kong | 1155617 | ⤷ Try it Free |
| Canada | 2781891 | ⤷ Try it Free |
| European Patent Office | 3266786 | ⤷ Try it Free |
| South Korea | 20180081523 | ⤷ Try it Free |
| Mexico | 2012006311 | ⤷ Try it Free |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for upadacitinib
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2506716 | C20200006 00317 | Estonia | ⤷ Try it Free | PRODUCT NAME: UPADATSITINIIB;REG NO/DATE: EU/1/19/1404; 18.12.2019 |
| 2506716 | 20C1009 | France | ⤷ Try it Free | PRODUCT NAME: UPADACITINIB OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/19/1404 20191218 |
| 2506716 | LUC00149 | Luxembourg | ⤷ Try it Free | PRODUCT NAME: UPADACITINIB OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/19/1404 20191218 |
| 2506716 | 132020000000022 | Italy | ⤷ Try it Free | PRODUCT NAME: UPADACITINIB IN QUALSIASI FORMA PROTETTA DAL BREVETTO DI BASE(RINVOQ); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/19/1404, 20191218 |
| 2506716 | 2020C/505 | Belgium | ⤷ Try it Free | PRODUCT NAME: UPADACITINIB OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; AUTHORISATION NUMBER AND DATE: EU/1/19/1404 20191218 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
